Benralizumab demonstrates strong efficacy in treating severe eosinophilic asthma and eosinophilic esophagitis (EoE), conditions in which disease pathology is largely driven by an overabundance of eosinophils and their activation via the IL‐5 pathway. Here, IL5 is linked to eosinophilic esophagitis.